• Proceedings of the PSK Conference
• /
• 2001.10a
• /
• pp.276.1-276.1
• /
• 2001

• 한국생물공학회:학술대회논문집
• /
• 2005.10a
• /
• pp.868-869
• /
• 2005

• 한국생물공학회:학술대회논문집
• /
• 2005.10a
• /
• pp.871-872
• /
• 2005

• 한국생물공학회:학술대회논문집
• /
• 2005.10a
• /
• pp.874-874
• /
• 2005

• Proceedings of the PSK Conference
• /
• 2001.10a
• /
• pp.255.3-256
• /
• 2001

• Proceedings of the Korean Biophysical Society Conference
• /
• 1998.06a
• /
• pp.13-13
• /
• 1998

The molecular mechanisms that arrest cardiomyocytes in the cell cycle during postnatal period remain largely unknown. The activity of CDKs control cell cycle progression, and this activity is regulated positively and negatively by association of CDKs with cyclins and cyelin dependent kinase inhibitors (CKIs) respectively.(omitted)

• Proceedings of the KTCVS Conference
• /
• 1993.06a
• /
• pp.70-70
• /
• 1993

• Bioinformatics and Biosystems
• /
• v.1 no.1
• /
• pp.28-37
• /
• 2006

Recent studies in molecular biology and proteomics have identified a significant number of novel diagnostic, prognostic, and therapeutic disease markers. However, validation of these markers in clinical specimens with traditional histopathological techniques involves low throughput and is time consuming and labor intensive. Tissue microarrays (TMAs) offer a means of combining tens to hundreds of specimens of tissue onto a single slide for simultaneous analysis. This capability is particularly pertinent in the field of cancer for target verification of data obtained from cDNA micro arrays and protein expression profiling of tissues, as well as in epidemiology-based investigations using histochemical/immunohistochemical staining or in situ hybridization. In combination with automated image analysis, TMA technology can be used in the global cellular network analysis of tissues. In particular, this potential has generated much excitement in cardiovascular disease research. The following review discusses recent advances in the construction and application of TMAs and the opportunity for developing novel, highly sensitive diagnostic tools for the early detection of cardiovascular disease.

• Korean Circulation Journal
• /
• v.53 no.7
• /
• pp.483-496
• /
• 2023

Background and Objectives: Atrial fibrillation (AF) is associated with decreased cardiac resynchronization therapy (CRT) benefits compared to sinus rhythm (SR). Effective biventricular (BiV) pacing is a determinant of CRT success, but AF can interfere with adequate BiV pacing and affect clinical outcomes. We investigated the effect of device-detected AF on clinical outcomes and optimal BiV pacing in patients with heart failure (HF) treated with CRT. Methods: We retrospectively analyzed 174 patients who underwent CRT implantation between 2012 and 2019 at a tertiary center. The optimal BiV pacing percentage was defined as ≥98%. Device-detected AF was defined as an atrial high-rate episode ≥180 beats per minute lasting more than 6 minutes during the follow-up period. We stratified the patients without preexisting AF at pre-implantation into device-detected AF and no-AF groups. Results: A total of 120 patients did not show preexisting AF at pre-implantation, and 54 had AF. Among these 120 patients, 19 (15.8%) showed device-detected AF during a median follow-up of 25.1 months. The proportion of optimal BiV pacing was significantly lower in the device-detected AF group than in the no-AF group (42.1% vs. 75.2%, p=0.009). The devicedetected AF group had a higher incidence of HF hospitalization, cardiovascular death, and all-cause death than the no-AF group. The device-detected AF and previous AF groups showed no significant differences regarding the percentage of BiV pacing and clinical outcomes. Conclusions: For HF patients implanted with CRT, device-detected AF was associated with lower optimal BiV pacing and worse clinical outcomes than no-AF.

• 한국생물공학회:학술대회논문집
• /
• 2005.10a
• /
• pp.295-295
• /
• 2005